Buck, Michael D https://orcid.org/0000-0002-9611-1199
Castro-Dopico, Tomás https://orcid.org/0000-0002-6964-5478
Schulz, Oliver
Cardoso, Ana https://orcid.org/0000-0002-4610-4337
Chakravarty, Probir
Legrave, Nathalie https://orcid.org/0000-0003-1172-4955
Henry, Conor M
Canton, Johnathan
Wu, Estelle https://orcid.org/0000-0002-6197-6694
Lee, Sonia
Rogers, Neil C https://orcid.org/0000-0001-8977-7585
Poirier, Enzo Z https://orcid.org/0000-0001-9795-2144
Stainier, William https://orcid.org/0009-0003-6182-4003
Bosteels, Victor
Childs, Eleanor
MacRae, James I https://orcid.org/0000-0002-1464-8583
Skehel, J Mark
Zelenay, Santiago https://orcid.org/0000-0002-6865-3978
Reis e Sousa, Caetano https://orcid.org/0000-0001-7392-2119
Funding for this research was provided by:
Cancer Research UK (FC001136)
UKRI | Medical Research Council (FC001136)
Wellcome Trust (FC001136)
Wellcome Trust (106973/Z/15/Z)
Wellcome Trust (223136/Z/21/Z)
EC | ERC | HORIZON EUROPE European Research Council (AdG 268670)
Boehringer Ingelheim Fonds
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (837951)
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (792770)
Article History
Received: 30 July 2025
Revised: 11 September 2025
Accepted: 28 September 2025
First Online: 29 October 2025
Disclosure and competing interests statement
: CRS is a founder of Adendra Therapeutics and owns stock options and/or is a paid consultant for Adendra Therapeutics, Montis Biosciences, and Bicycle Therapeutics, all unrelated to this work. CRS also holds appointments as Visiting Professor at Imperial College London and at King’s College London and as honorary professor at University College London. CRS is also a member of the Advisory Editorial Board of The EMBO Journal . This has no bearing on the editorial consideration of this article for publication. The authors declare no competing interests.